Breast最新文献

筛选
英文 中文
P050: Genomic risk assessment with Oncotype DX in youngwomen (age ≤ 40 years old) with early-stage ER+/HER2-/N0 breast cancer P050:早期ER+/HER2-/N0乳腺癌年轻女性(年龄≤40岁)的Oncotype DX基因组风险评估
IF 5.7 2区 医学
Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103933
R. Iosifidou, G. Xepapadakis, V. Venizelos, C. Markopoulos, K. Papazisis, N. Tsoulos, G. Kapetsis, S. Giannoulakis, M. Paraskeva, M. Kaparelou, G. Lainakis, A. Fotarelli, F. Pavlidou, E. Fountzilas, E. Saloustros, S. Karageorgopoulou, S. Triantafillidou, S. Intzes, F Koinis
{"title":"P050: Genomic risk assessment with Oncotype DX in youngwomen (age ≤ 40 years old) with early-stage ER+/HER2-/N0 breast cancer","authors":"R. Iosifidou, G. Xepapadakis, V. Venizelos, C. Markopoulos, K. Papazisis, N. Tsoulos, G. Kapetsis, S. Giannoulakis, M. Paraskeva, M. Kaparelou, G. Lainakis, A. Fotarelli, F. Pavlidou, E. Fountzilas, E. Saloustros, S. Karageorgopoulou, S. Triantafillidou, S. Intzes, F Koinis","doi":"10.1016/j.breast.2025.103933","DOIUrl":"10.1016/j.breast.2025.103933","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103933"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P046: Preclinical efficacy and safety evaluation of CAR-T cell therapy against TROP2 for treatment of triple negative breast cancer P046: CAR-T细胞抗TROP2治疗三阴性乳腺癌的临床前疗效和安全性评价
IF 5.7 2区 医学
Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103929
S. Sun, X. Wang, S. Zhang, Y. Xu, X Ma
{"title":"P046: Preclinical efficacy and safety evaluation of CAR-T cell therapy against TROP2 for treatment of triple negative breast cancer","authors":"S. Sun, X. Wang, S. Zhang, Y. Xu, X Ma","doi":"10.1016/j.breast.2025.103929","DOIUrl":"10.1016/j.breast.2025.103929","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103929"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P118: Role of artificial intelligence and mHealth for the prevention, detection and management of breast cancer patients P118:人工智能和移动医疗在乳腺癌患者预防、检测和管理中的作用
IF 5.7 2区 医学
Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103984
V. Mitova, M.D. Plachkova, I Gavrilov
{"title":"P118: Role of artificial intelligence and mHealth for the prevention, detection and management of breast cancer patients","authors":"V. Mitova, M.D. Plachkova, I Gavrilov","doi":"10.1016/j.breast.2025.103984","DOIUrl":"10.1016/j.breast.2025.103984","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103984"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P038: Hypoxia-regulated NDRG1 predicted breast cancer survival P038:缺氧调节的NDRG1预测乳腺癌生存
IF 5.7 2区 医学
Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103923
W. Numprasit, J.A Quinn, J. Edwards, C Thuwajit
{"title":"P038: Hypoxia-regulated NDRG1 predicted breast cancer survival","authors":"W. Numprasit, J.A Quinn, J. Edwards, C Thuwajit","doi":"10.1016/j.breast.2025.103923","DOIUrl":"10.1016/j.breast.2025.103923","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103923"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P028: Confronting Barriers in HER2-Positive Metastatic Breast Cancer: Insights from a Phase II Trial of Inetetamab, Pyrotinib, and Chemotherapy P028:面对her2阳性转移性乳腺癌的障碍:来自Inetetamab, Pyrotinib和化疗的II期试验的见解
IF 5.7 2区 医学
Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103915
J. Zhao, Z. Zhou, L. Ding, J. Ye, T. Long, G. Zou, Y. Cai, J. Chai, H. Yao, Y Wang
{"title":"P028: Confronting Barriers in HER2-Positive Metastatic Breast Cancer: Insights from a Phase II Trial of Inetetamab, Pyrotinib, and Chemotherapy","authors":"J. Zhao, Z. Zhou, L. Ding, J. Ye, T. Long, G. Zou, Y. Cai, J. Chai, H. Yao, Y Wang","doi":"10.1016/j.breast.2025.103915","DOIUrl":"10.1016/j.breast.2025.103915","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103915"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P002: Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial 在monarchE试验中,HR+、HER2-、淋巴结阳性、高危早期乳腺癌(EBC)患者原发肿瘤的基因组和转录组学分析
IF 5.7 2区 医学
Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103896
C.S. Rubenstein, N. Turner, J.S. Reis-Filho, M.P. Goetz, C. Desmedt, S. Chandarlapaty, H. Sasano, C.L. Arteaga, S. Loi, S.L. Graff, D. Liu, V. Rodrik-Outmezguine, A. Sireci, H. Won, L.M. Litchfield, M. Munoz, S Johnston
{"title":"P002: Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial","authors":"C.S. Rubenstein, N. Turner, J.S. Reis-Filho, M.P. Goetz, C. Desmedt, S. Chandarlapaty, H. Sasano, C.L. Arteaga, S. Loi, S.L. Graff, D. Liu, V. Rodrik-Outmezguine, A. Sireci, H. Won, L.M. Litchfield, M. Munoz, S Johnston","doi":"10.1016/j.breast.2025.103896","DOIUrl":"10.1016/j.breast.2025.103896","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103896"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them 细胞周期蛋白依赖性激酶4和6抑制剂(CDK4/6i):耐药机制和在哪里找到它们。
IF 5.7 2区 医学
Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2024.103863
L. Foffano , L. Cucciniello , E. Nicolò , I. Migliaccio , C. Noto , C. Reduzzi , L. Malorni , M. Cristofanilli , L. Gerratana , F. Puglisi
{"title":"Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them","authors":"L. Foffano ,&nbsp;L. Cucciniello ,&nbsp;E. Nicolò ,&nbsp;I. Migliaccio ,&nbsp;C. Noto ,&nbsp;C. Reduzzi ,&nbsp;L. Malorni ,&nbsp;M. Cristofanilli ,&nbsp;L. Gerratana ,&nbsp;F. Puglisi","doi":"10.1016/j.breast.2024.103863","DOIUrl":"10.1016/j.breast.2024.103863","url":null,"abstract":"<div><div>CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR + HER2 negative (HER2-) metastatic breast cancer (BC) when combined with endocrine therapy. Nonetheless, despite significant research efforts, the mechanisms of de novo and acquired resistance to CDK4/6i have not yet been fully elucidated, highlighting the need for a deeper understanding of these process. Additionally, the importance of dissecting CDK4/6i resistance from endocrine resistance for personalized treatment is increasingly recognized.</div><div>Liquid biopsy has emerged as a minimally invasive tool for identifying circulating biomarkers of resistance through the integration of multiparametric and dynamic assessments that encompass ctDNA, CTCs, exosomes, and epigenetic ctDNA alterations, representing a promising perspective for the clinical characterization of treatment resistance and guiding post-progression strategies to improve patient outcomes.</div><div>Aim of this review is summarize potential mechanisms of CDK4/6i resistance, along with the advantages of using liquid biopsy to identify resistance biomarkers in HR+/HER2- MBC patients treated with CDK 4/6 inhibitors.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103863"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncological outcomes following extreme oncoplastic breast conserving surgery (eOPBCS) for locally advanced breast cancer (LABC): A systematic review and meta-analysis 局部晚期乳腺癌(LABC)极端保乳手术(eOPBCS)后的肿瘤预后:一项系统综述和荟萃分析。
IF 5.7 2区 医学
Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2024.103869
Megan Chua Wern Ee , Ashley Lee Shi Hui , Wong Hung Chew , Emmeline Elaine Cua-Delos Santos , Sean Li Siwei , Sng Ming Xian , Qin Xiang Ng , Serene Goh Si Ning
{"title":"Oncological outcomes following extreme oncoplastic breast conserving surgery (eOPBCS) for locally advanced breast cancer (LABC): A systematic review and meta-analysis","authors":"Megan Chua Wern Ee ,&nbsp;Ashley Lee Shi Hui ,&nbsp;Wong Hung Chew ,&nbsp;Emmeline Elaine Cua-Delos Santos ,&nbsp;Sean Li Siwei ,&nbsp;Sng Ming Xian ,&nbsp;Qin Xiang Ng ,&nbsp;Serene Goh Si Ning","doi":"10.1016/j.breast.2024.103869","DOIUrl":"10.1016/j.breast.2024.103869","url":null,"abstract":"<div><h3>Introduction</h3><div>Locally advanced breast cancer (LABC) accounts for 5 % of new breast cancer diagnoses in developed countries and 30–60 % in developing regions. Historically, treatment relied on mastectomy guided by the Halstedian theory. Advances in neoadjuvant chemotherapy (NACT), breast-conserving surgery (BCS), and radiation have transformed treatment into a multimodal approach. Extreme oncoplastic BCS (eOPBCS) has expanded the boundaries of BCS, enabling large-volume resections with breast reshaping. However, its oncologic outcomes compared to mastectomy remain unclear, particularly in LABC.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis were conducted following PRISMA guidelines (PROSPERO: CRD42024535182). Studies involving eOPBCS for LABC were reviewed, and those comparing outcomes with mastectomy were included in the meta-analysis. The primary outcomes were overall survival (OS), disease-free survival (DFS), and local recurrence rates (LRR). Data were synthesized using a random-effects model.</div></div><div><h3>Results</h3><div>Of 866 identified studies, 33 were included in the systematic review and 4 in the meta-analysis, involving 2902 patients with LABC. Among them, 16.1 % underwent eOPBCS. Patients receiving eOPBCS were younger, had larger tumours, and more frequently underwent axillary clearance. The pooled hazard ratio (HR) for OS comparing mastectomy to eOPBCS was 1.72 (95% CI 1.04-2.83). Meanwhile, HRs for DFS (1.11, 95% CI 0.60-2.08) and LRR (0.67, 95% CI 0.38-1.18) showed that there were no statistically significant differences but a trend toward lower recurrence rates with mastectomy.</div></div><div><h3>Conclusion</h3><div>eOPBCS demonstrates comparable to superior oncological outcomes to mastectomy in LABC, offering a promising option for selected patients. However, slightly elevated local recurrence rates, though not statistically significant, highlight the importance of careful patient selection and further research. High-quality prospective studies are essential to validate these findings and refine criteria for incorporating eOPBCS into routine clinical practice.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103869"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P016: Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With first or second line CDK 4/6 Inhibitors and Endocrine Therapy in Egypt P016:在埃及接受一线或二线cdk4 /6抑制剂和内分泌治疗的转移性乳腺癌患者的实际临床结果和毒性
IF 5.7 2区 医学
Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103909
A. Kortoma, H. El Wakeel, N. Gobran, H Elghazawy
{"title":"P016: Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With first or second line CDK 4/6 Inhibitors and Endocrine Therapy in Egypt","authors":"A. Kortoma,&nbsp;H. El Wakeel,&nbsp;N. Gobran,&nbsp;H Elghazawy","doi":"10.1016/j.breast.2025.103909","DOIUrl":"10.1016/j.breast.2025.103909","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103909"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143576392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P100: Analysis of immune homeostasis (IH) and systemic inflammation (SI) using CDSS/«LeHaim»for monitoring luminal “B” breast cancer (BC) P100: CDSS/«LeHaim»监测腔内B型乳腺癌(BC)的免疫稳态(IH)和全身炎症(SI)分析
IF 5.7 2区 医学
Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103967
D. Melnikov, I. Pushina, Y. Silacheva, O. Melnikova, V. Vaganov, A Lifshits
{"title":"P100: Analysis of immune homeostasis (IH) and systemic inflammation (SI) using CDSS/«LeHaim»for monitoring luminal “B” breast cancer (BC)","authors":"D. Melnikov,&nbsp;I. Pushina,&nbsp;Y. Silacheva,&nbsp;O. Melnikova,&nbsp;V. Vaganov,&nbsp;A Lifshits","doi":"10.1016/j.breast.2025.103967","DOIUrl":"10.1016/j.breast.2025.103967","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103967"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143576718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信